MISSISSAUGA, ON, Oct. 29 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND)
announced that it has been informed that additional time will be required for
the U.S. Food and Drug Administration to complete its review of the Company's
New Drug Application for CIP-TRAMADOL ER, an extended-release formulation of
the analgesic tramadol. The Company previously disclosed that it expected the
review to be completed by mid-October 2008.
